Champions Oncology Inc. (CSBR)
CSBR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.90
-1.08% on the day
Market cap
$68.2M
Micro cap
Revenue · 2025
$59.4M
+4.4% on 2024
Net income · 2025
-$1K
-0.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CSBR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000771856 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $59.4M |
| Net income | -$1K |
| Operating income | -$1.1M |
| Net margin | -0.0% |
| Operating margin | -1.9% |
| Revenue growth | +4.4% |
| Cash | $7.1M |
| Total assets | $28.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2016-06-10 |
| Latest annual report | 10-K | 2026-07-27 |
| Latest quarterly / interim | 10-Q | 2026-09-11 |
| Latest current report | 8-K | 2026-09-10 |
| Latest proxy | DEFA14A | 2026-08-28 |
Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NMRA | Neumora Therapeutics Inc. | $0.3702 | -15.34% | $69.6M |
| GRML | Greenland Mines Ltd. | $5.54 | -7.97% | $73.9M |
| OKYO | OKYO Pharma Limited | $1.44 | -0.17% | $75.4M |
| CGTX | Cognition Therapeutics Inc. | $0.8017 | -6.44% | $76.2M |
| LONA | LeonaBio Inc. | $6.43 | +4.30% | $60.6M |
| PTHS | Pelthos Therapeutics Inc. | $20.29 | +3.94% | $77.7M |
| CRDF | Cardiff Oncology Inc. | $1.01 | -2.88% | $78.6M |
| KLRS | Kalaris Therapeutics Inc. | $2.23 | -1.33% | $53.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier